Detailed Narrative
Q1 FY26 Performance Overview
Sanjivani Parenteral Limited reported a steady Q1 FY26 performance with revenue growing 8.9% year-on-year to INR17.9 crores. EBITDA increased by 10.8% year-on-year to INR2.7 crores, resulting in an EBITDA margin of 15%, an improvement from 14.7% in the same period last year. However, Profit After Tax remained flat at INR1.7 crores, primarily due to higher depreciation and interest expenses during the quarter. The growth was driven by revenues from newer products and volume expansion in existing markets.
Macroeconomic Headwinds and Supply Chain Challenges
The quarter unfolded against a volatile global environment, marked by geopolitical tensions in the Middle East that disrupted major shipping corridors like the Red Sea, leading to increased transit times and costs. Global container logistics also faced strain with tight container availability and congestion at transshipment hubs, causing consignment delays. Despite these challenges, management noted that underlying demand remains intact and the logistical situation is already showing signs of easing, with expectations for normalization progressively over the year.
New Ventures Update (Pune & Prague)
The SPL Infusion Private Limited (Pune plant), in which Sanjivani holds 60% equity, has completed validation batches and final audits. Commercial license is expected this month, with production commencing by the end of August or first week of September. This plant is projected to ramp up to 65-70% capacity in its first year, aiming for INR75-80 crores in revenue. The Alevia Healthcare (Prague JV), a nutraceutical venture in Europe where Sanjivani holds 45% equity, has started small order processing, and its income is expected to be recognized in Q4 FY26.
Business Verticals and Product Mix
Sanjivani's business is categorized into three verticals: the base business (formulation, sales, exports), SPL Infusion (IV products), and Alevia Healthcare (nutraceuticals). The export-domestic revenue mix for Q1 FY26 was 73.7% to 26.3%. The product mix comprised 50.2% injectables, 49.3% tablets, and 0.4% nutraceuticals. The CDMO business, which is a small portion of the Indian market, is targeted to achieve around 20% growth this year.
Financial Performance Details (Margins, Depreciation, Debt)
While the overall market was under pressure, leading to a slight decline in gross margins, the company managed to grow revenue and offset this by controlling other expenses. Other expenses decreased sequentially from INR4 crores to INR2.5 crores due to cost optimization and fewer audits. Depreciation increased by 13% year-on-year, reflecting recent capital expenditure. The company's debt levels reduced from INR8 crores last quarter to INR6 crores this quarter, primarily due to minor repayments of working capital limits.
Growth Strategy and Product Pipeline
The company continues to focus on life-saving drugs and exports to over 25 countries. It added around eight new products to its portfolio across Q1 and Q2. Management anticipates EBITDA margins to improve in FY27 as these new products mature and economies of scale are achieved. Latin America and MENA regions are significant contributors, with LATAM expected to be a key growth driver for the company in the near term.
Shareholder Value and Outlook
In Q4 FY25, Sanjivani declared a dividend for the first time, reflecting improved financial performance and commitment to rewarding shareholders. For FY26, the company targets total revenue of INR75-80 crores and aims to maintain base business EBITDA margins around 15%. Management remains confident in delivering stronger performance for the rest of FY26, supported by a diversified market presence, product portfolio, and planned new introductions.